Medivir AB (publ)
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Sweden, the Nordic region, rest of Europe, and internationally. The company offers Xerclear for the treatment of labial herpes under the Zoviduo name; and Olysio to treat hepatitis C. It also develops Remetinostat, a histone deacetylase (HDAC) inhibitor that has completed Phas… Read more
Medivir AB (publ) (MVR0) - Total Liabilities
Latest total liabilities as of September 2025: €65.50 Million EUR
Based on the latest financial reports, Medivir AB (publ) (MVR0) has total liabilities worth €65.50 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Medivir AB (publ) - Total Liabilities Trend (2021–2024)
This chart illustrates how Medivir AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Medivir AB (publ) Competitors by Total Liabilities
The table below lists competitors of Medivir AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sonic Interfreight Public Company Limited
BK:SONIC
|
Thailand | ฿438.37 Million |
|
Ado Optronics
TWO:3516
|
Taiwan | NT$1.15 Billion |
|
OPCOM Holdings Bhd
KLSE:0035
|
Malaysia | RM106.72 Million |
|
Mineral Commodities Ltd
AU:MRC
|
Australia | AU$32.71 Million |
|
TPC Power Holding Public Company Limited
BK:TPCH
|
Thailand | ฿3.82 Billion |
|
Acon Optics Communications Inc.
TWO:6820
|
Taiwan | NT$376.78 Million |
|
INTERSHOP Communications Aktiengesellschaft
XETRA:ISHA
|
Germany | €24.19 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Medivir AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medivir AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medivir AB (publ) (2021–2024)
The table below shows the annual total liabilities of Medivir AB (publ) from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €57.07 Million | -18.45% |
| 2023-12-31 | €69.99 Million | +69.02% |
| 2022-12-31 | €41.41 Million | -24.27% |
| 2021-12-31 | €54.68 Million | -- |